PRESS RELEASE published on 05/14/2024 at 16:15, 6 months 6 days ago VAZIVA SA: ROBUST BUSINESS GROWTH IN 2023 - SALES UP 91% - A YEAR OF INVESTMENTS TO SUPPORT GROWTH Vaziva SA reports robust 91% sales growth in 2023, driven by key account customers and strategic investments. EBITDA up 154%, operating income up 262% EBITDA Sales Growth VAZIVA SA Operating Income Investments
BRIEF published on 04/29/2024 at 17:50, 6 months 21 days ago VAZIVA SA: Exponential growth in 2023 Financial Results Fintech European Expansion Growth Vaziva Large Accounts
BRIEF published on 04/23/2024 at 11:05, 6 months 28 days ago VAZIVA SA organizes a webinar for its shareholders Shareholders Webinar 2023 Results VAZIVA SA Registration
BRIEF published on 04/16/2024 at 18:05, 7 months 4 days ago VAZIVA SA announces its financial calendar for 2024 Financial Calendar Press Release VAZIVA SA Annual Results Turnover
BRIEF published on 03/26/2024 at 10:10, 7 months 26 days ago VAZIVA SA organizes a webinar for its individual shareholders Webinar VAZIVA SA Euronext Growth® Paris Individual Shareholders Dematerialization
BRIEF published on 03/21/2024 at 10:15, 8 months ago VAZIVA SA organizes a webinar for its shareholders following its IPO Shareholders Webinar VAZIVA SA Social Endowment Euronext Growth® Paris
BRIEF published on 03/19/2024 at 11:25, 8 months 2 days ago VAZIVA SA organizes a webinar for its shareholders on March 26, 2024 Artificial Intelligence VAZIVA SA Euronext Growth® Paris Shareholder Webinar Dematerialized Securities
BRIEF published on 03/13/2024 at 08:05, 8 months 8 days ago VAZIVA SA takes a new step by joining Euronext Growth® Paris Euronext Growth Paris VAZIVA SA Fintech Social Endowment Stock Market Expansion
PRESS RELEASE published on 03/13/2024 at 08:00, 8 months 8 days ago VAZIVA ANNOUNCES THE LISTING OF ITS STOCKS ON EURONEXT GROWTH®PARIS Vaziva announces the listing of its stocks on Euronext Growth® Paris, marking a significant milestone for the fintech specializing in personalized social endowments VAZIVA Fintech Euronext Growth® Paris Stocks Listing Social Endowments
PRESS RELEASE published on 01/30/2024 at 18:00, 9 months 21 days ago VAZIVA SA: ONGOING BULLISH TREND - ANNUAL SALES 2023 UP +79% TO €25.6M VAZIVA SA reports an ongoing bullish trend in annual sales, with a 79% increase to €25.6M in 2023, driven by successful offering in the booming Employees benefits’ market for dematerialized social endowments VAZIVA SA Bullish Trend Annual Sales Dematerialized Social Endowments Mastercard Partnership
Published on 11/21/2024 at 13:00, 36 minutes ago Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 36 minutes ago Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 36 minutes ago Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography
Published on 11/21/2024 at 13:00, 36 minutes ago Nextech3D.ai Spin-Out Rebrands as FOTOgpt.ai to Usher in a New Era of AI-Powered Photography
Published on 11/21/2024 at 13:00, 36 minutes ago Clean Air Metals Announces Positive Results from Innovative Seismic Survey at the Escape Deposit Down-Plunge Extension
Published on 11/21/2024 at 12:35, 1 hour ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 21 minutes ago Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 06:58, 6 hours 38 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 16 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 19 hours 51 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 19 hours 51 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 5 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
